Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0663
Abstract: Background In clinical trials that assess novel therapeutic agents in patients with non-small-cell lung cancer (NSCLC), early endpoints (e.g. progression-free survival [PFS] and objective response rate) are often evaluated as indicators of biological drug activity,…
read more here.
Keywords:
trial;
early endpoints;
non small;
cancer ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.672916
Abstract: Early endpoints, such as progression-free survival (PFS), are increasingly used as surrogates for overall survival (OS) to accelerate approval of novel oncology agents. Compiling trial-level data from randomized controlled trials (RCTs) could help to develop…
read more here.
Keywords:
trial;
early endpoints;
level;
oncology ... See more keywords